Novo Nordisk Sues Amneal Over Vagifem Generic

Law360, New York (August 15, 2013, 5:12 PM ET) -- Novo Nordisk Inc. on Wednesday sued generic-drug maker Amneal Pharmaceuticals LLC in New Jersey federal court, accusing its rival of patent infringement over a planned generic version of hormone replacement drug Vagifem.

According to Novo — the U.S. unit of Danish drugmaker Novo Nordisk A/S — Bridgewater, N.J.-based Amneal’s plan to make 10 microgram estradiol vaginal tablets infringes on U.S. Patent Number 7,018,992, which covers Vagifem’s method of administration.

“Plaintiffs will be harmed substantially and irreparably if defendants are not enjoined from infringing the ‘992 patent,”...
To view the full article, register now.